Abiopharma

🔍 Abecassis Michael M (Director)

Company: PharmaCyte Biotech, Inc. (PMCB)

Report Date: 2025-04-25

Detailed Transactions and Holdings:

• Acquired 37,500 shares of Common Stock (Direct)
  Date: 2025-12-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 39,167.00 | transaction_form_type: 4
• Sold 16,875 shares of Common Stock at $1.02 per share (Direct)
  Date: 2025-12-12 | Code: F | equity_swap_involved: 0 | shares_owned_after: 22,292.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-04-25 | Code: H | nature_of_ownership: By Transplant Consulting LLC | shares_owned_after: 800.00
• Acquired 63,233 shares of Stock Option (Right to Buy) at $1.22 per share (Derivative)
  Date: 2025-04-25 | Code: A | Expires: 2035-04-24 | equity_swap_involved: 0 | shares_owned_after: 63,233.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction.
• F2: The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Abecassis. This transaction is late due to an inadvertent administrative error and not any error of Mr. Abecassis.